

Edasalonexent

Chemical Properties


CAS No. : 1204317-86-1

Formula: C₃₁H₄₂N₂O₃

Molecular Weight: 490.68

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Edasalonexent (CAT-1004) is an orally available NF-κB inhibitor designed to improve Duchenne muscular dystrophy.
Targets(IC50)	NF-κB
In vitro	Edasalonexent effectively inhibits the pathogenic NF-κB subunit p65/RelA in vitro[3].
In vivo	In vivo, Edasalonexent effectively improves the phenotype of mdx mice in terms of activity, muscle mass and function, injury, inflammation, fibrosis, and cardiac pathology associated with voluntary wheel running[3].

Solubility Information

Solubility	DMSO: 80 mg/mL (163.04 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (5.09 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.038 mL	10.1899 mL	20.3799 mL
5 mM	0.4076 mL	2.038 mL	4.076 mL
10 mM	0.2038 mL	1.019 mL	2.038 mL
50 mM	0.0408 mL	0.2038 mL	0.4076 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hammers DW, et al. Disease-modifying effects of orally bioavailable NF- κ B inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341.

Donovan JM, et al. A Novel NF- κ B Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639.

Hammers DW, et al. Disease-modifying effects of orally bioavailable NF- κ B inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481